EyeWorld Asia-Pacific September 2015 Issue

53 EWAP PHARMACEUTICALS Sepetmber 2015 surgery, the dilation is generally maintained unless inflammatory agents like prostaglandins are released. These will induce pupillary constriction, he explained. “That’s why not only is it important to dilate the patient with dilating agents, it’s also important to use a nonsteroidal to protect the eye from the production of prostaglandins and the pupillary constriction that occurs with their release,” Dr. Donnenfeld said, adding that such nonsteroidals are the key to maintaining pupillary dilation throughout the case. The problem with nonsteroidals given preoperatively, however, is that these are irrigated out during the surgery with the balanced salt solution. “Omidria with the addition of phenylephrine and ketorolac allows the infusion of nonsteroidal into the eye during the surgery, and that is extraordinarily effective at maintaining pupil size,” Dr. Donnenfeld said. “The nonsteroidal that is infused during the surgery protects the patient and the physician from pupillary constriction.” Dr. Donnenfeld views the Diagnosing dry - from page 51 DATE MEETING VENUE 2016 February 19-21 World Ophthalmology Congress 2016 (WOC) www.woc2016.org Guadalajara Mexico March 25-29 The 31st Asia-Paci c Academy of Ophthalmology Congress (APAO) www.apaophth.org Taipei Chinese Taipei May 6-10 ASCRS-ASOA Symposium and Congress (ASCRS) www.ascrs.org New Orleans USA July 28-30 29th Asia-Paci c Association of Cataract and Refractive Surgeons Annual Meeting (APACRS) www.apacrs.org Bali Indonesia September 10-14 XXXIV Congress of European Society of Cataract and Refractive Surgery (ESCRS) www.escrs.org Copenhagen Denmark October 15-18 Annual Meeting of American Academy of Ophthalmology (AAO) www.aao.org Chicago USA CALENDAR OF MEETINGS approval of Omidria as a landmark moment in ophthalmology. “This is the first time we have an intracameral FDA-approved medication to be used routinely during cataract surgery,” he said, adding that the future of cataract surgery will be drug delivery. In the future he believes the use of drops is going to be diminished, with Omidria paving the way. “We’re going to look back on that and say, ‘That’s what started the trend,’” Dr. Donnenfeld said. He is hopeful that the nonsteroidal may prove helpful as well, potentially reducing the risk of macular thickening. “I believe that placing the medication into the eye from surgery is going to provide an additional value in obtaining macular function,” Dr. Donnenfeld said. EWAP Editors’ note: Dr. Donnenfeld has financial interests with Alcon, Allergan (Irvine, Calif.), Bausch + Lomb (Bridgewater, NJ), and Omeros. Dr. Holland has financial interests with Omeros. Contact information Donnenfeld : ericdonnenfeld@gmail.com Holland : eholland@holprovision.com Diagnostics’ TearScan “provides real-time point-of-care quantitative results for lactoferrin and IgE tear diagnostic tests,” the company said. “IgE should be a great marker for allergic eye disease, but we need to validate those tests,” Dr. Holland said. Bottom line “Clinicians still need to take a good clinical history and perform a thorough clinical slit lamp evaluation before devising a treatment plan for their dry eye patients,” Dr. de Luise said. “In aggregate, history, exam, and diagnostic testing can bring us closer to the correct diagnosis, which will then lead to the correct treatment strategy.” The more tests a clinician has in the armamentarium, however, the more the field is recognizing that disease progression occurs. Common to many other ocular disorders, the more progressed a patient’s dry eye, the more difficult to treat. “We have older patients who didn’t have their ocular surface disease diagnosed until late in the disease course and the result is poor quality of vision and unhappy patients,” Dr. Holland said. “The more advanced the disease the more difficult it will be to treat and improve. We have been diagnosing ocular surface disease the same way for decades. It is time we use these new technologies to make us better and more efficient clinicians,” he said. Eventually, Dr. Holland thinks clinicians will have the ability to get a variety of diagnostics run from one or two tear samples, and that may become a reality within the next few years. “Researchers are working on it now,” he said. “These types of tests will be less expensive, be faster because it’s one sample, and will give us a lot more data.” EWAP Editors’ note: Dr. de Luise has no financial interests related to this article. Dr. Holland has financial interests with TearLab, Tear Science, and Rapid Pathogen Screening. Contact information De Luise: vdeluisemd@gmail.com Holland: Eholland@holprovision.com